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Caveolae are membrane micro-domains enriched in cholesterol, sphingolipids and
caveolins, which are transmembrane proteins with a hairpin-like structure. Caveolae
participate in receptor-mediated trafficking of cell surface receptors and receptor-mediated
signaling. Furthermore, caveolae participate in clathrin-independent endocytosis of
membrane receptors. On the one hand, caveolins are involved in vascular and cardiac
dysfunction. Also, neurological abnormalities in caveolin-1 knockout mice and a link
between caveolin-1 gene haplotypes and neurodegenerative diseases have been reported.
The aim of this article is to present the rationale for considering caveolae as potential
targets in cardiovascular and neurological diseases.
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INTRODUCTION
Caveolins are a family of proteins with a hairpin-like structure.
This structure is necessary to form unique membrane micro-
domains known as caveolae. To our knowledge Yamada (1955)
first identified caveolae in gallbladder epithelium. The author
observed: “The free cell surface between microvilli shows larger
cave-like depressions, likewise representing caveolae intracellulares,
containing a dense material.” Twenty years later, Dulhunty and
Franzini-Armstrong (1975) provided a detailed account of the
appearance of caveolae using freeze-fracture replicas of the cell
surface membrane of frog skeletal muscles. They defined the
structure as: “elliptical invaginations of the plasmalemma which
open to the outside by a narrow ‘neck’ of approximately 20 nm.”
Rothberg et al. (1992) identified and named as caveolin the key
component in such membrane micro-domains. Caveolins are a
family of proteins with similar structure and, to date, three mem-
bers have been identified. The first member, VIP21-caveolin or
caveolin-1, is widely expressed in tissues, especially in adipocytes,
fibroblasts, epithelial cells and vascular endothelial cells; caveolin-
2 interacts with and is co-expressed with caveolin-1; and, M-
caveolin or caveolin-3, is mainly expressed in striated (skeletal
and smooth) muscle myocytes (Scherer et al., 1996; Tang et al.,
1996; Way and Parton, 1996; see Gratton et al., 2004 and Gazzerro
et al., 2010 for review). Caveolae are enriched in cholesterol
and sphingolipids (Severs, 1981; Rothberg et al., 1990; Parton,
1994) and the high content in cholesterol allows manipulating the
Abbreviations: GPCR, G-protein-coupled receptor; GRK, G protein-coupled
receptor kinases.
system using sterol-binding agents (e.g., methyl-β-cyclodextrin
or filipin). These compounds have been indeed invaluable to
study the physiological role of caveolae. Vertical domains that
usually span both cell membrane leaflets and are enriched
in cholesterol and sphingolipids are known as lipids rafts.
Caveolae are considered lipid rafts in as much as they contain
caveolins.
The two most obvious roles of caveolae are to recruit mem-
brane proteins at specific membrane domains and to partic-
ipate in protein internalization (recently reviewed in Shvets
et al., 2014). Also they can regulate numerous enzyme activ-
ities, including that of adenylate cyclase (AC), eNitric oxide
synthase (eNOS), and several kinases and serine/threonine
phosphatases (Toya et al., 1998; Carman et al., 1999; Razani
and Lisanti, 2001; Hnasko and Lisanti, 2003). Hence, cave-
olins/caveolae are not just organizers or scaffolds that local-
ize signaling proteins but regulators of important cell events.
This perspective article focuses on the therapeutic potential of
targeting caveolins/caveolae in cardiovascular and neurological
diseases.
CAVEOLAE AND CARDIOVASCULAR DISEASES
Altered endothelium appears as a common factor in a variety of
serious diseases (Berman et al., 1990; Harrison, 1991; Lerman
and Burnett, 1992; Quyyumi, 1998; Vincent et al., 2011; Salmon
and Satchell, 2012). Caveolins and caveolae are very relevant to
maintain the endothelial cell membrane integrity in both struc-
ture and function (Williams and Lisanti, 2004; Yuan and Rigor,
2010). Atherosclerosis, a frequent disease in Western societies, is
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due to deposition of cholesterol-rich lipoproteins in the endothe-
lium of blood vessels. Transcytosis, which is a vesicle-mediated
mechanism of transcellular transport of molecules, is very impor-
tant to remove lipid deposits and to avoid endothelial activation
and vessel occlusion. Recent evidence shows that caveolin-1 and
caveolae are involved in metabolic switching, endothelial transcy-
tosis and regulate vascular inflammation (Pavlides et al., 2014;
Shiroto et al., 2014).
Often, heart abnormalities course with abnormal calcium han-
dling, for instance, in atrial fibrillation (Hove-Madsen et al.,
2004) and hypertrophy (Gwathmey and Morgan, 1985; Cuneo
and Grassi de Gende, 1988). Phospholipase C and hetero-trimeric
Gq proteins regulate intracellular calcium concentrations. In an
elegant study Guo et al. (2011) identified Gq proteins in cave-
olae and reported that adult caveolin-3-containing ventricular
cardiomyocytes show oscillating Ca2+ waves that are extinguished
by blocking the interaction between caveolin-3 and the α sub-
unit of Gq proteins. Therefore, caveolin-3 is directly involved in
regulating contractility andmay be a target for heart hypertrophy.
Mutations in the caveolin-1 gene and decreased expression of
caveolin-1 have been identified in patients with pulmonary arte-
rial hypertension (Desai, 2012), a disease with high morbidity.
Caveolin-1 null mice display a marked reduction in life span due
to a combination of cardiac hypertrophy, pulmonary fibrosis and
pulmonary hypertension (Park et al., 2003). Interestingly, dou-
ble KO mice for caveolin-1 and the myocyte-selective subtype,
caveolin-3, are viable but display severe cardiomyopathy (Park
et al., 2002). Although Feiner et al. (2011) could not demon-
strate significantly different levels of caveolin-3 in failing hearts,
a significant correlation existed in human failing hearts between
levels of caveolin-3 and Ca2+-ATPase, a marker of the heart-
failure phenotype. To our knowledge, Fujimoto in (1993) was
the first to identify an ion pump (Ca2+) in caveolae. Since then
several studies have confirmed a link between caveolins/caveolae
and ion carriers. In cardiomyocytes the Na+/Ca2+ exchanger is
very important for heart functionality. The exchanger may inter-
act with caveolin-1 but may also formmacromolecular complexes
with caveolin-3 and annexin A5 (Bossuyt et al., 2002a,b). In
left ventricular myocardial samples from human failing hearts
the annexin A5-interaction site in the exchanger is not acces-
sible and the interaction between the carrier and caveolin-3 is
reduced. The data suggests that caveolin-3-containing structures
are relevant for Ca2+ handling in cardiac cells (Camors et al.,
2006). The involvement of caveolae in different cardiovascular
diseases makes caveolin-based therapeutic approaches an attrac-
tive possibility to combat myocardial ischemia, heart failure and
pulmonary hypertension (see Fridolfsson and Patel, 2013).
Cumulative evidence in the last decade has shown that key
proteins in cardiomyocyte function interact with caveolins. Thus,
caveolins not only participate in membrane positioning but also
in ion channel regulation. Many ion transporters interact with
caveolins and/or are located in caveolae (see Balijepalli and
Kamp, 2008, for review). The human inward rectifying voltage-
gated HERG K+ channel (Trudeau et al., 1995) interacts with
caveolin-1 and reduces its activity when caveolin is up-regulated
(Lin et al., 2008). Cell surface expression and degradation of
HERG is also controlled by caveolin-3 via a complex of these
two proteins with the Nedd4-2 ubiquitin ligase (Guo et al.,
2012) and via dynamin-mediated endocytosis (Massaeli et al.,
2010). Caveolin-3 interacts with another K+ inward rectifying
channel (Kir2.1) whose current densities are affected by muta-
tions in caveolin-3 (Vaidyanathan et al., 2013). Mutations in the
cardiac hNa(v)1.5 channel lead to cardiac phenotypic manifes-
tations; interestingly, caveolin-3 mutations identified in patients
with inherited long-QT syndrome result in enhanced currents
via this specific sodium channel (Vatta et al., 2006, see Wilde
and Brugada, 2011, for review). Mutations in the caveolin-3 gene
are also related to sudden infant death syndrome, with higher
risk in carriers with further mutations in the hNa(v)1.5 gene
(Arnestad et al., 2007; Cronk et al., 2007). Finally, caveolae may
regulate ion handling by recruiting ion transporters and regu-
latory molecules (Yarbrough et al., 2002; Shibata et al., 2006;
Palygin et al., 2008). A computer-based investigation supports
the possibility that accumulation of ions in caveolae may lead to
delayed-repolarization-induced arrhythmias (Besse et al., 2011).
It is also of interest that caveolin-3 may be linked to and alters the
function of hyperpolarization-activated cyclic nucleotide-gated
channel 4, which regulates cardiac pacemaker activity (Ye et al.,
2008). Balijepalli and Kamp (2008) provide a detailed account of
the role of caveolae in arrhythmogenesis.
CAVEOLAE AND NEUROLOGICAL DISEASES
As neurological diseases are very diverse we present below a few
examples of results that support a link between caveolins/caveolae
and the two most prominent neurodegenerative disorders in
developed countries: Parkinson’s and Alzheimer’s diseases.
α-synuclein is a protein that often accumulates in the brain
of Parkinson’s disease patients (Polymeropoulos et al., 1997;
Arawaka et al., 1998; Takeda et al., 1998). α-synuclein seems to
cause neurodegeneration by interacting with signaling proteins
and/or altering receptor-mediated signaling pathways. Examples
of proteins targeted by α-synuclein are protein kinase C, extra-
cellular signal-regulated kinase (ERK) and phospholipase D
(Ostrerova et al., 1999; Iwata et al., 2001; Ahn et al., 2002).
Biochemical studies using α-synuclein-overexpressing human
neuroblastoma cells show a correlation between altered ERK sig-
naling and deregulation of caveolin-1 expression (Hashimoto
et al., 2003). In parkinsonian patients but not in controls, six
homozygous haplotypes of the caveolin-1 gene have been iden-
tified Darvish et al. (2013). Furthermore, the leucine-rich repeat
kinase 2 (LRRK2) is located in the neck of caveolae in a human cell
model (Alegre-Abarrategui et al., 2009). Mutations in the gene of
this kinase are linked to Parkinson’s disease (Di Fonzo et al., 2005;
Gilks et al., 2005). Overall, the results establish a link between
caveolin-1 and molecular hallmarks of Parkinson’s disease.
Alzheimer’s disease has two pathological hallmarks: intracel-
lular neurofibrillary tangles, made up of aberrantly phospho-
rylated tau protein and plaques, made up of amyloidogenic
(aberrant) processing of the amyloid precursor protein (APP),
that leads to Aß peptide. The enzyme that cleaves APP to give
Aß (BACE-1) physically associates to lipid-raft proteins (Hattori
et al., 2006). Caveolin-3 is up-regulated in glial cells surrounding
plaques and enhances the amyloidogenic route of APP process-
ing (Nishiyama et al., 1999). Furthermore, caveolins physically
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associate to presenilins (Nishiyama et al., 1999) that are also rel-
evant molecules in the pathophysiology of Alzheimer’s disease.
Therefore, caveolae were suspected to be involved in processing of
APP, a transmembrane protein requiring integrity of cell surface
mechanisms for a correct physiological function. The first indica-
tion for this view came in 1998 from the identification of the Aß
peptide in detergent-insoluble compartments (Lee et al., 1998).
More recently caveolin-1 knockout mice are considered a non-
mutational model for Alzheimer’s disease based on the acceler-
ated aging and neurodegeneration phenotype (Head et al., 2010).
The mice displayed astrogliosis and increased Aβ and hyper-
phosphorylated tau and, noteworthy, expression of caveolin-1 in
neurons from the animals led to a significant decrease in Aβ
expression (Head et al., 2010).
THERAPEUTIC POSSIBILITIES: TARGETING CAVEOLIN
EXPRESSION
Caveolins/caveolae are now considered as therapeutic targets for
a variety of diseases. Inhibitors are more frequent than activators
as drugs targeting enzymes. Drugs targeting receptors are more
often antagonists (blockers) than agonists (activators). Matters
in the case of caveolins/caveolae are not as straightforward as
caveolins have neither orthosteric binding sites for function regu-
lation nor regulatory sites. To our knowledge, no small molecule
targeting caveolins has been developed. Difficulties in target-
ing this type of membrane proteins likely underlie this lack of
drug development and limit the use of caveolins as drug tar-
gets. One way to circumvent this issue is the use of anti-caveolin
antibodies (Oh and Schnitzer, 1999; Gumbleton et al., 2003).
Another limitation is the absence of suitable readouts for cave-
olin action. In sharp contrast there are highly suitable and high
throughput possibilities for both enzymes and receptors. A sig-
nificant alternative intervention to either increase or decrease
caveolin expression would be gene or cell therapy, direct target-
ing of caveolin using antisense and siRNA approaches, modu-
lation of cellular cholesterol levels or caveolar lipid content and
the use of inhibitory peptides derived from caveolin scaffolding
domains.
Regulation of cholesterol levels or caveolar lipid content may
thus be attempted for therapeutic purposes. The use of statins
such as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase inhibitors decrease caveolin-1 levels (Kusama et al.,
2001), which can involve blockade of the production of meval-
onate, an intermediate in isoprenoid and cholesterol synthesis
(Kirschmeier et al., 2001). Simvastatin may also alter lipid raft
composition (Zhuang et al., 2005).
Despite the fact that gene therapy has not delivered the
promised results, new viral vectors may be suitable to target
caveolae with efficacy in the affected tissue. This would prevent
side effects due to indiscriminate targeting of multiple tissues.
Viruses can use caveolae-dependent or –independent mecha-
nisms to enter the cell. One may take advantage of this fact to
design therapeutic strategies using viral vectors that target caveo-
lae (see next section). Analogously, polymeric structures may tar-
get caveolae and interfere with caveolae-mediated physiological
or pathological actions. As an example, polysorbitol-based trans-
porter delivery of small interfering RNA use caveolae for cell entry
(Islam et al., 2012). Dendrimers successful in delivering genes via
caveolae (Huang et al., 2014) merit attention for either enhanc-
ing or depressing caveolae-mediated events. Similarly, complexes
formed by protamine, dextran, and solid lipid nanoparticles may
target caveolae after intravenous administration to mice (Delgado
et al., 2012).
THERAPEUTIC POSSIBILITIES: FROM CELL THERAPY TO
BLOCKADE OF CAVEOLAE-MEDIATED TRAFFIC AND
TARGETING OF CAVEOLIN-PROTEIN/RECEPTOR
INTERACTIONS
Cell therapy is providing new hopes for a variety of diseases. Cell
therapy using autologous stem cells engineered to express spe-
cific caveolins may be considered a further possibility to colonize
tissues with caveolins/caveolae-related pathologies. To colonize
lungs, Ghaedi et al. (2013) have been successful in develop-
ing caveolin-1 expressing alveolar epithelial cells from human
induced pluripotent stem (iPS) cells. Similarly, other iPS-derived
cells may have the potential to colonize endothelium in dif-
ferent tissues or, alternatively, iPS cells may differentiate into
neurons (Chung et al., 2013) or, eventually into cardiomyocytes.
To increase safety of cell therapy, generation of tumor-free iPS cell
has been recently possible (Phillips, 2014; Zhang et al., 2014).
Caveolins/caveolae may be indirectly targeted by block-
ing membrane fusion events related to endocytosis. Dynasore,
an inhibitor of the GTPase activity of dynamin may pre-
vent the entry into cells of papilloma viruses that require
caveolae- and clathrin-mediated endocytosis (Abban et al., 2008).
Paramyxoviruses (Sánchez-Felipe et al., 2014) and neurotropic
viruses such as Japanese encephalitis virus (Zhu et al., 2012)
also use a caveolae and dynamin-dependent mechanism to enter
into cells. Therefore, these viruses constitute a basis to design
caveolae-targeting vectors.
Skeletal muscle expressing the Pro104Leumutant of caveolin-3
leads to atrophy, and mice with this mutation serve as a model of
limb-girdle muscular dystrophy 1C (Minetti et al., 1998; Galbiati
et al., 2000; Hagiwara et al., 2000). The transforming growth fac-
tor type I β receptor kinase inhibitor, Ki26894, is able to restore
both in vitro muscle cell deficiencies and muscle atrophy and
weakness displayed by mutant mice (Ohsawa et al., 2012). A sim-
ilar intervention could be envisaged for restoring cardiomyocyte
function in patients with cardiac atrophy.
A further possibility is to modulate proteins located in cave-
olae to activate caveolae-mediated restorative events. Members
of the G-protein-coupled receptor (GPCR) superfamily are a
relevant example. GPCRs are targets of approximately 40% of
compounds used in human therapy. Agonist and/or antagonist
modulation of their activity can lead to increases or decreases
in the expression levels of caveolins. In addition, it seems pos-
sible that GPCRs can form heteroreceptor complexes with cave-
olins. Interactions may modify the pharmacological properties
in turn making possible the design of compounds selective for
GPCR protomers present in such complexes. Examples of the
direct link between caveolae and GPCRs are given in the next
section.
Many proteins and receptors (e.g., GPCR) contain putative
caveolin binding domains (Couet et al., 1997). For instance,
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caveolin-1 interacting proteins contain the canonical caveolin-1
binding domain, φXφXXXXφ or φXXXXφXXφ (where φ = Trp,
Phe or Tyr). In some pathologies, reducing the ability of caveolins
to couple to the signaling machinery at the inner plasma mem-
brane may result in an efficacious intervention. For instance, the
introduction of synthetic caveolin-scaffolding-domain peptides
into cells may inhibit caveolin-protein interactions. In support of
this, internalization of the caveolin scaffolding domain may be
achieved by fusion of the domain with a 16-amino acid peptide
of the Drosophila antennapedia homeodomain. By this approach
platelet activating-factor-induced NO production and microvas-
culature permeability was reduced in tumor bearing animals
(Zhu et al., 2004). It should be noted that neovascularization is
required in initial steps of metastatic colonization of tissues and
that caveolin-1 regulates metastasis in bladder cancer (Thomas
et al., 2011).
Use of indirect caveolin-modulating strategies may also be
effective against cardiovascular and neurological diseases. As
detailed in the previous and the following sections, the bi-
directional relationship that caveolins have with a number of
interacting proteins and receptors could be exploited to re-
expressing or targeting caveolins for up- and down-regulation.
Examples would be targeting some GPCRs. The use of GPCR-
selective agonist or antagonist, many of which are in current
clinical use, may also affect directly (via receptor-caveolin inter-
actions) or indirectly (via second messenger and signal cascade
activation, e.g., MAPK) caveolin expression levels. Via activa-
tion of some GPCRs we could control or re-program caveolin
expression levels to explore therapeutic outcomes in heart and
brain.
CAVEOLAE AND GPCRs
Cumulative evidence points to caveolae and caveolins as impor-
tant regulators of GPCR traffic and function thus raising thera-
peutic potential in targeting caveolae or GPCRs in caveolae (see
Figure 1). Caveolins form homo-oligomers (Monier et al., 1995;
Sargiacomo et al., 1995) and interact with G proteins (Li et al.,
1995). GPCRs are not homogeneously distributed on the cell sur-
face and a significant amount of receptors are in caveolae (Ginés
et al., 2001). GPCRs may even interact with caveolins (Burgueño
et al., 2003, 2004). Even important elements in GPCR-mediated
signaling such as G protein-coupled receptor kinases (GRKs) have
binding motives for caveolins and the interaction regulates GRK
function (Carman et al., 1999). Depending on cell type, and prob-
ably on caveolin subtype, GPCR agonists may enrich receptors in
caveolae or do the opposite. In fact, agonist-induced activation of
adenosine receptors may recruit them into caveolae for caveolae-
mediated internalization (Ginés et al., 2001; Escriche et al., 2003).
FIGURE 1 | Scheme of caveolins/caveolae participation in the cell
biology of GPCRs. Caveolins/caveolae regulate agonist binding and
signaling and GPCR traffic. Some interventions with therapeutic
potential are: (A) targeting caveolin-binding domains in the GPCR. (B)
Regulating synthesis and expression of caveolins by means of cell
therapy or small interfering RNA. (C) Targeting receptors to regulate
caveolae-dependent endocytosis. (D) Regulation of cholesterol levels, for
instance by using statins.
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In contrast, in cardiomyocytes, these adenosine receptors are
enriched in caveolae until activation leads to translocation out
of caveolae (Lasley et al., 2000; Lasley and Smart, 2001). This
differential behavior may be taken into account when targeting
caveolae via GPCRs.
Specific G-protein-related signaling components are enriched
in lipid rafts/caveolae meaning that these structures affect G-
protein-coupling efficacy and signaling selectivity (see Chini and
Parenti, 2004 and Insel et al., 2005, for review). An exhaustive
review of the reports linking caveolins/caveolae to the biology
of GPCRs is out of the scope of the present perspective arti-
cle. Some few examples will, however, be provided to give a hint
of the relevant connections between the receptors and caveolae.
Localization of the α1A adrenergic GPCR in lipid rafts restricts
their conformation and basal activity while allowing a substan-
tial coupling to the G protein and a robust signaling upon agonist
activation (Lei et al., 2009). Caveolin-2 participates in receptor
signaling even in a simple system constituted by human embry-
onic kidney (HEK-293) cells expressing a GPCR (D1) for the
neurotransmitter dopamine (Yu et al., 2004). Caveolin is also
involved in agonist-induced recruitment and internalization of
a GPCR for the regulatory molecule adenosine (subtype 1, A1
receptor) (Ginés et al., 2001). In fact, Escriche et al. (2003) pro-
vided morphological evidence of caveolae-mediated internaliza-
tion, endosomal sorting and A1 receptor recycling. Very relevant
for caveolae-based drug discovery, Klaasse et al. (2005) reported
small-molecule allosteric modulators of adenosine A1 GPCRs
that affect internalization of the receptor. Adenosine deaminase,
also interacts with A1 GPCRs, enhances signaling and appears to
be an allosteric modulator of caveolae-mediated receptor inter-
nalization (Ginés et al., 2001). Caveolae disruption by cholesterol
depletion alters the regulation by adenosine subtype 2 (A2A) of
anion secretion in epithelial cells (Lam et al., 2009). Adenosine
A2A GPCRs are up-regulated in atrial fibrillation and their block-
ade results in restoring the abnormal calcium handling in car-
diomyocytes from patients (Hove-Madsen et al., 2006; Llach et al.,
2011). Adenosine A2A GPCRs may also form homodimers or
heteromers with other receptors. The complexes are unique enti-
ties with specific signaling properties (Hillion et al., 2002; Canals
et al., 2004). Therefore, differential expression of A2A GPCR
monomer/homomers/heteromers in membrane micro-domains
is an interesting possibility for altered functional properties that
should be further explored. Endothelin subtype B receptor in
endothelial cells is mainly present in caveolae and its activation by
endothelin leads to rapid caveolae-dependent internalization. It is
likely that activation of such receptors present in caveolae leads to
rapid caveolae-mediated trafficking (Oh et al., 2012).
The selective advantage of reperfusion after ischemic injury
to minimize the consequences of a second ischemic episode has
been known for long (see Yellon et al., 1998 for review). From
the finding that the increase in extracellular adenosine was help-
ful in anoxic heart conditions (Jacob and Berne, 1961; Ely and
Berne, 1992) several studies have shown that adenosine (Kitakaze
et al., 1993; Pelleg, 1993) and other compounds acting on GPCRs
(Avkiran and Haworth, 2003; Minguet et al., 2012; Dragasis et al.,
2013) regulate heart-ischemia-reperfusion and preconditioning.
As reviewed by Stary et al. (2012) caveolins are necessary for
ischemic preconditioning. Targeting for instance opioid recep-
tors may help in enhancing the reperfusion benefits. Opioid-
induced preconditioning alters the architecture of the myocyte
and increases the number of caveolae (Tsutsumi et al., 2010; Stary
et al., 2012). The use of knockout animals for caveolin-3 has
shown that this protein is essential for in vivo opioid-induced
preconditioning (Tsutsumi et al., 2010).
Future work will help on understanding how caveolin-protein
and caveolin-GPCR interactions may help in combating cardio-
vascular and neurological diseases.
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